Atea Pharmaceuticals Clarifies Board Composition Amid Director Nominations

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

March 21, 2025 - NEW YORK, NY - Atea Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare and infectious diseases, today issued a statement regarding director nominations.

The company announced that its Board of Directors has nominated a slate of highly qualified and experienced individuals to serve as directors of the company. The nominees include:

• Dr. Maria Rodriguez, a renowned expert in the field of infectious diseases and a highly respected leader in the biopharmaceutical industry.
• Mr. John Smith, a seasoned executive with a strong track record of success in the pharmaceutical industry.
• Dr. Jane Doe, a leading expert in the field of rare diseases and a pioneer in the development of innovative treatments for these conditions.

The company's Board of Directors is committed to ensuring that the company is well-positioned for long-term success and is dedicated to making the best possible decisions for the benefit of all stakeholders.

"We are pleased to present this slate of highly qualified and experienced nominees to serve as directors of the company," said Dr. Maria Rodriguez, Chairman of the Board. "Each of these individuals brings a unique set of skills and expertise that will be invaluable in helping to drive the company's growth and success."

The company's shareholders will have the opportunity to vote on the nominees at the company's upcoming annual meeting. The meeting is scheduled to take place on [insert date] at [insert time] at [insert location].

For more information, please contact: [Insert name] [Insert title] Atea Pharmaceuticals [Insert phone number] [Insert email]